Heron Therapeutics, Inc. 2014 Form 10-K Summary
Business context and reporting period
Heron Therapeutics, formerly A.P. Pharma, is a pre-commercial biotechnology company developing injectable drug-delivery products using its Biochronomer polymer platform. The filing covers the fiscal year ended December 31, 2014. The company changed its name in January 2014, completed a 1-for-20 reverse stock split, and began trading on Nasdaq under HRTX in January 2014.
- Lead candidate: SUSTOL (APF530), an extended-release granisetron injection for acute- and delayed-onset chemotherapy-induced nausea and vomiting.
- Other programs: HTX-011 for post-operative pain, HTX-019 for CINV, and HTX-003 for chronic pain and opioid addiction.
- The company had no approved or commercialized products and generated no product revenue.
Financial performance and liquidity
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $54.8 million | $32.5 million | Up $22.3 million |
| General and administrative expense | $19.7 million | $21.9 million | Down $2.2 million |
| Loss from operations | $74.6 million | $54.5 million | Loss increased $20.1 million |
| Net loss | $76.4 million | $55.3 million | Loss increased $21.1 million |
| Net loss per share | $2.87 | $3.42 | Lower loss per share due primarily to higher share count |
| Net cash used in operating activities | $60.3 million | $40.8 million | Use increased $19.5 million |
| Cash and cash equivalents at year-end | $72.7 million | $72.3 million | Up $0.4 million |
| Working capital | $60.1 million | $65.9 million | Down $5.8 million |
| Accumulated deficit | $315.2 million | $238.9 million | Increased $76.4 million |
There was no meaningful operating margin because the company had no revenue; operating expenses were entirely research and development and general and administrative costs. Research and development represented approximately 74% of operating expenses.
Financing activities provided $62.1 million in 2014, including $58.9 million of net proceeds from a June 2014 common stock and pre-funded warrant offering and $3.1 million from stock option exercises. Investing activities used $1.4 million, primarily for property and equipment. The resulting net increase in cash was $0.4 million.
Convertible notes had a stated principal balance of approximately $5.3 million and a carrying value of $1.6 million at year-end. The notes bear interest at 6%, mature in 2021, are secured by substantially all company assets, and may be prepaid at the holders’ option. Conversion of the outstanding principal and accrued interest would result in approximately 6.7 million shares being issued.
Contractual obligations totaled $2.5 million, consisting of $1.6 million of operating lease obligations and $0.9 million of purchase obligations. The company reported no off-balance-sheet arrangements.
Material changes versus the prior comparable period
- R&D expense increased 69% to $54.8 million, primarily because of the SUSTOL Phase 3 HEC study, manufacturing development and scale-up activities, and new product development.
- G&A expense decreased 10% to $19.7 million, mainly because 2013 included higher stock-based compensation associated with executive management changes.
- Other expense increased to $1.8 million from $0.8 million, including a $0.9 million impairment of manufacturing-related equipment made obsolete by supply-chain changes following FDA manufacturing concerns.
- Operating cash usage increased to $60.3 million from $40.8 million, substantially offset by equity financing proceeds.
- Shares outstanding increased to 29.2 million at December 31, 2014 from 23.6 million at December 31, 2013, reflecting the 2014 offering and equity exercises.
- Fourth-quarter 2014 net loss was $20.6 million, compared with $14.0 million in the fourth quarter of 2013. Fourth-quarter operating expenses were $19.5 million, including $14.2 million of R&D and $5.3 million of G&A.
Guidance, outlook, commentary, risks and unusual items
- Management expected to complete enrollment in the SUSTOL HEC Phase 3 study by the end of the first quarter of 2015 and intended to resubmit the SUSTOL NDA around mid-2015, including HEC study results.
- Management stated that SUSTOL was not expected to be commercially available before 2016, if at all.
- The company expected R&D expense to increase in 2015 as it completed the HEC study and advanced HTX-011 and HTX-019.
- Management believed existing working capital was sufficient to fund operations through 2015, including SUSTOL regulatory activities and certain early-stage clinical programs. Additional financing would be needed for expanded development, acquisitions, or significant commercialization investments.
- SUSTOL had received two FDA Complete Response Letters. Remaining issues included chemistry, manufacturing and controls, contract-manufacturer deficiencies, human-factors testing, and reanalysis of clinical results under updated guidelines.
- The company relied on a small number of third-party manufacturers and did not own manufacturing facilities. Commercial scale-up, validation, cost control and FDA approval remained significant contingencies.
- Key competitive risks included ALOXI, generic granisetron and ondansetron, potential generic palonosetron, and other emerging CINV therapies. SUSTOL patents had U.S. expiration dates ranging from January 2016 to September 2024.
- The company had a history of operating losses, negative operating cash flow and an accumulated deficit. It stated that it had no current means of generating material operating cash flow and might need additional equity, debt or collaboration financing.
- Potential dilution was substantial: approximately 20.1 million shares were reserved for future issuance through options, warrants, the employee purchase plan and convertible notes, compared with 29.2 million shares outstanding at year-end.
- The 2014 impairment charge of $0.9 million was an unusual non-cash item related to manufacturing equipment rendered unusable by supply-chain changes.
- The financial statements received an unqualified audit opinion, and management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2014.
Important facts for investors to verify
- Whether the SUSTOL HEC Phase 3 study was completed successfully and whether the planned NDA resubmission occurred on schedule.
- Whether the FDA accepted the resubmission and resolved the prior CMC, manufacturing, human-factors and clinical-data concerns.
- Cash burn, remaining liquidity and the timing and terms of any subsequent financing.
- The potential dilution and control implications of the convertible notes, warrants and outstanding stock options.
- Commercial manufacturing readiness, contract-manufacturer capacity, validation status and expected cost of goods.
- Whether SUSTOL or any other candidate obtains regulatory approval and achieves reimbursement and market acceptance against generic and branded competitors.
- The company’s ability to fund operations beyond 2015 without materially reducing development programs or issuing securities on unfavorable terms.